In pretreated patients with advanced small cell lung cancer, treatment with the combination of apatinib and single-agent chemotherapy showed promising efficacy and was well-tolerated, data from a prospective phase 2 study.
In multiple gastrointestinal tumor types, the combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile, according to data presented at the 2021 ASCO Gastrointestinal Cancers Symposium.
Higher doses of telomerase inhibitor imetelstat demonstrated better overall survival, spleen response, and symptom response in patients with myelofibrosis who are relapsed after or refractory to therapy with Janus kinase inhibitors in the phase 2 IMbark study.
Given the higher efficacy of carfilzomib seen in recent phase 2 trials, investigators sought to determine if carfilzomib could replace bortezomib in the current standard of care triplet induction regimen in standard and intermediate risk NDMM, but the study failed.
By eating a balanced, low-fat diet and daily portions of vegetables, fruit, and grains, women have a 21% lower risk of dying from breast cancer, according to research to be presented during the upcoming 2019 ASCO Annual Meeting in Chicago.